Abstract
Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.
Original language | English (US) |
---|---|
Pages (from-to) | 646-648 |
Number of pages | 3 |
Journal | Journal of drugs in dermatology : JDD |
Volume | 6 |
Issue number | 6 |
State | Published - Jun 2007 |
Externally published | Yes |
ASJC Scopus subject areas
- Dermatology